Our R&D

Dedication and Focus

A leader in pharmaceutical research and development in Hong Kong, Jacobson’s in-house research and development team developed over 30%* of the new drugs registered by generic drug manufacturers in Hong Kong.

We aim to develop premium generics based on our established product development know-how and deep market insight. Focusing on specialized formulations and having acquired specific manufacturing skills and know-how for certain difficult-to-make products, such as controlled-release formulations, sterile products, suppositories and enemas, we possess a host of drug registrations with unique formulae allowing us to command a competitive position in certain selected segments of market.

* Industry report by Frost & Sullivan 2015

Collaboration

At Jacobson, we value partnership and collaboration. Our current research and development team cooperates closely with a panel of formulation scientists and research institutions both locally and abroad. Our connections with research institutions and university hospitals also enhance our competence in both formulation and clinical pursuits.

In our collaboration with Hong Kong Institute of Biotechnology, we have established a new research and development center which is equipped with advanced facilities for the development of formulation and coating technologies to be applied on premium generics and proprietary Chinese medicines. The center operated by Jacobson Research Laboratory Limited is now fully functional after its completion in end of 2016.

Projects and Awards

The Group actively explores collaborations with local and overseas research and academic institutions for technology developments and has undertaken several collaborative projects with local and overseas R&D institutions and companies, such as:

Project with Hong Kong Institute of Biotechnology (HKIB)

The collaboration project with HKIB for “Real-time Monitoring and End Point Determination of Pharmaceutical Powder Blending in Both R&D and Manufacturing by Near-Infrared Spectroscopic (NIRS) Technology” was kick-started in March 2017. This is a government-funded research project for real-time quality control of manufacturing process, being a new pharmaceutical production technology in Hong Kong, largely enhancing the product quality and efficiency of the manufacturing process.

Collaboration with Nano & Advanced Materials Institute Limited (NAMI)

The collaborative research project with NAMI on “Novel Nanoparticles for Pre-clinical Diagnosis for Early Alzheimer Detection and Drug Development” has achieved encouraging progress and recognition since its launch in June 2016 with the winning of the Gold Medal Award at the 45th International Exhibition of Inventions of Geneva.

Thanks to the success of this project, a newly commercialized product patent-filed and trademarked as “NanoAZDTM” was launched in April 2017. The product was first promoted at the Alzheimer’s Association International Conference in London in July 2017 and received encouraging feedback; recognized for its potential on human applications because of the technological breakthroughs and its safe nature.

Jacobson Research
Laboratory

A fully owned subsidiary of Jacobson Pharma Corporation Limited, Jacobson Research Laboratory Limited is the first pharma and healthcare research company in Hong Kong established to provide comprehensive and integrated research and development services to both local and oversea industries.

Jacobson Research aims to be a leading player in the pharmaceutical research arena in the Asia Pacific region, distinguished by its methodological approach and one-stop service of delivering solutions-based scientific and professional expertise on research and development projects.

State-of-the-art Facilities

With a commitment of robust investments, Jacobson Research aims to pursue the state-of-the-art research facilities and laboratories support to meet the needs of the leading scientific minds.

Its laboratory in HKIB operates in a simulated GMP standard environment (Class 100,000 Cleanroom) ensuring smooth technology and product transfer to PIC/s (Pharmaceutical Inspection Cooperation Scheme) GMP manufacturing plant with an array of equipment and instruments, which include:

  • Production line for various finished dosage forms (e.g. tablet, capsule, pellet, cream, lotion, suppository, granule, novel biotechnological products)
  • Equipment for physical, chemical and microbiological analyses (e.g. HPLCs, UV, dissolution apparatus, disintegration tester, NIR)